DelveInsight’s Hunter Syndrome Market Insights Report offers a detailed analysis of the disease, its causes, symptoms, diagnostics modalities, and treatment options.
The report also offers comprehensive insights into Hunter Syndrome market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing market size growth forward.
Some of the key highlights from the Hunter Syndrome Market Insights:
The total diagnosed Hunter Syndrome prevalent population in the 7 major markets was 1,166 in 2020.
In the United States, there were approximately 515 identified as Hunter Syndrome cases in 2020
As per DelveInsight’s analysis, it is observed that in the diagnosed Hunter Syndrome prevalence, patients are higher in number in the 7 MM out of which mild type forms a bigger patient pool than the severe type of MPS II. The initial symptoms and findings associated with the indication usually become apparent in children from 2–4 years of age.
Major players such as JCR Pharmaceuticals, Takeda, Denali Therapeutics and Regenxbio, and others are involved in developing therapies for the treatment and management of Hunter Syndrome. These therapies are currently under different stages of development.
Key pipeline therapies in the Hunter Syndrome market include JR-141SHP-609/ TAK-609, DNL310, RGX-121, among others.
Learn more by requesting for sample @ Hunter Syndrome Market Landscape
Hunter Syndrome: Overview
Hunter syndrome is also known as Mucopolysaccharidosis type II (MPS II). It is a condition that affects many different parts of the body and mainly affects males. It is a progressive disorder, but the rate of progression varies among affected individuals.
It is a rare, X-linked disorder caused due to a deficiency of the lysosomal enzyme iduronate-2-sulfatase, which plays a major role in the catabolism of glycosaminoglycans (GAG).
For more insights into Disease, causes and treatment, reach out @ Hunter Syndrome Treatment Landscape
Hunter Syndrome Epidemiology Segmentation
The Hunter Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Hunter Syndrome Prevalence
Severity Specific Hunter Syndrome Prevalence
Diagnosed and Treatable Cases of Hunter Syndrome
Visit for more @ Hunter Syndrome Epidemiological Insights
Hunter Syndrome Market
Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of Hunter Syndrome. Owing to the positive outcomes of the several products during the developmental stage by key players such as JCR Pharmaceuticals, Takeda, Denali Therapeutics and Regenxbio, the market is expected to witness a significant positive shift in the Hunter Syndrome Market Size.
Hunter Syndrome Pipeline Therapies and Key Companies
JR-141: JCR Pharmaceuticals
SHP-609/ TAK-609: Takeda
DNL310: Denali Therapeutics
For more information, visit Hunter Syndrome Market Analysis, Patient Pool and Emerging Therapies
Hunter Syndrome Market Drivers
Rising prevalent population
Scope of the Report
Descriptive overview of Hunter Syndrome, covering causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight into Hunter Syndrome epidemiology and treatment in the 7MM
Current and emerging therapies for Hunter Syndrome
Hunter Syndrome market drivers and barriers
Key Questions Answered in the Report
What was the Hunter Syndrome market share (%) distribution in 2017 and how it would look like in 2030?
During the forecast period (2017-2030), what will be the total market size for Hunter Syndrome as well as market size by therapy across the 7MM?
What are the most important discoveries from the 7MM market, and which country will have the greatest Hunter Syndrome market size throughout the projected period (2017-2030)?
At what CAGR, the Hunter Syndrome market is expected to grow at 7MM during the forecast period (2017-2030)?
Table of Contents
Competitive Intelligence Analysis for Hunter Syndrome
Hunter Syndrome Market Overview at a Glance
Executive Summary of Hunter Syndrome
Hunter Syndrome Epidemiology and Market Methodology
Hunter Syndrome Epidemiology and Patient Population
Hunter Syndrome Patient Journey
Treatment Algorithm, Current Treatment, and Medical Practices
Key Endpoints in Hunter Syndrome Clinical Trials
Hunter Syndrome Marketed Therapies
Hunter Syndrome Emerging Therapies
Hunter Syndrome: 7 Major Market Analysis
Access and Reimbursement Overview of Hunter Syndrome
Hunter Syndrome Market Drivers
Hunter Syndrome Market Barriers
Intrahepatic Cholangiocarcinoma (ICCA) Market
COVID 19 Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020
Cervical Dysplasia Market
Diabetic Kidney Disease Market
Acute Respiratory Distress Syndrome (ARDS) Market
Acute Kidney Injury (AKI) Market
Renal Anemia Market
Hunter Syndrome Market experiences a positive push as the pharma companies spot the untapped opportunities
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States